1-环丙基-3-甲基丁烷-2-酮 | 66557-34-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-环丙基-3-甲基丁烷-2-酮
• 英文名称: 1-Cyclopropyl-3-methylbutan-2-one
• CAS: 66557-34-4
• 化学式: C₈H₁₄O
• 分子量: 126.199
• InChiKey: JBHWZPCFTXKFBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-环丙基-3-甲基丁烷-2-酮 在 吡啶硼烷 作用下， 生成 N'-(1-cyclopropyl-3-methylbutan-2-yl)-4-methylbenzenesulfonohydrazide
  参考文献：
  名称：

  Mercury(II)-mediated cyclisation of hydroperoxyalkylcyclopropanes: a new route to cyclic peroxides

  摘要：

  Aldehydes, RCHO (R = Me, Et, (i)Pr, and c-C6H11), have been converted via alkylation, cyclopropanation, oxidation, condensation with p-tosylhydrazine, reduction and perhydrolysis into 2-hydroperoxyalkylcyclopropanes, RCH(OOH)CH2c-C3H5, and thence by cycloperoxymercuriation and reductive demercuriation into the corresponding 3-alkyl-5-ethyl-1,2-dioxolanes.

  DOI：

  10.1016/0040-4039(91)80453-d
• 作为产物：
  描述：

  2-甲基-5-己烯-3-醇 在 铜 、 pyridinium chlorochromate 、 锌 作用下， 生成 1-环丙基-3-甲基丁烷-2-酮
  参考文献：
  名称：

  Mercury(II)-mediated cyclisation of hydroperoxyalkylcyclopropanes: a new route to cyclic peroxides

  摘要：

  Aldehydes, RCHO (R = Me, Et, (i)Pr, and c-C6H11), have been converted via alkylation, cyclopropanation, oxidation, condensation with p-tosylhydrazine, reduction and perhydrolysis into 2-hydroperoxyalkylcyclopropanes, RCH(OOH)CH2c-C3H5, and thence by cycloperoxymercuriation and reductive demercuriation into the corresponding 3-alkyl-5-ethyl-1,2-dioxolanes.

  DOI：

  10.1016/0040-4039(91)80453-d

文献信息

• TRIAZOLE ACC INHIBITORS AND USES THEREOF
  申请人：Gilead Apollo, LLC

  公开号：US20170166584A1

  公开（公告）日：2017-06-15

  The present invention provides triazole compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.

  本发明提供了三唑化合物，可用作乙酰辅酶A羧化酶（ACC）的抑制剂，以及其组合物和使用方法。
• Hepatitis C Virus Inhibitors
  申请人：Belema Makonen

  公开号：US20100080772A1

  公开（公告）日：2010-04-01

  The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这些化合物的药物组合物以及使用这些化合物治疗HCV感染的方法。
• [EN] COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS<br/>[FR] ASSOCIATIONS D'INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015005901A1

  公开（公告）日：2015-01-15

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组合物，以及抑制NS5A蛋白功能的方法。
• [EN] LINKED DIBENZIMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DU DIBENZIMIDAZOLE LIÉS
  申请人：ENANTA PHARM INC

  公开号：WO2010091413A1

  公开（公告）日：2010-08-12

  The present invention discloses linked dibenzimidazole derivatives, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了联苯二咪唑衍生物，或其药学上可接受的盐、酯或前药，其抑制含RNA的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• HEPATITIS C VIRUS INHIBITORS
  申请人：Qiu Yao-Ling

  公开号：US20110064695A1

  公开（公告）日：2011-03-17

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药： 这些化合物抑制RNA含病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上述新型抗病毒化合物，包括含有这些化合物的药物组合物，以及用于治疗或预防受试者需要此类治疗的病毒（特别是HCV）感染的方法。